Joris Vandeputte | Past President
IABS

Dr. Veterinary Medicine, virologist, active in global networking in human and animal health, vaccines and diagnostics, global disease control, one health, public affairs with EU, WHO, Asian and African authorities and experienced in vaccine translational development. CV in brief:

• Research Virology at Ghent University, faculty of Veterinary Medicine: discovery of H1N1 influenza in swine and its zoonotic role, in collaboration with WHO reference Centre in Munich. Vaccination in swine and bovine.
• Global Head of business units vaccines for swine and ruminants, director scientific support and director international regulatory affairs at Rhône-Mérieux, Merial, now Boehringer Ingelheim.
• Part of the initial GAVI/Vaccine Fund team, creating sustainable collaboration between GAVI/The Vaccine Fund and the EU.
• VP resource mobilization for tuberculosis vaccines and support to tuberculosis vaccine development at TBVI.
• GALVMED: supporting the animal vaccine networks in Africa
• European research programs: work package leader, regulatory, of EU/IMI projects ZAPI (platform technologies for human and animal vaccines, pandemic preparedness), VAC2VAC ( 3R’s in vitro batch control) and MANCO (development of monoclonal antibodies against SARS-CoV-2); participation in EU/IMI projects DRIVE (flu vaccine effectiveness) and INNO4VAC (human infection models), Co-Lead regulatory in the CEPI/HERA project, the Global consortium on human challenge studies in hunt for transmission-blocking coronavirus vaccines
• Others:  overview of animal challenge models for COVID-19 vaccines, correlates of protection for COVID-19 vaccines, participating in strategies on pandemic preparedness, high pathogenic influenza and African Swine Fever control.
• Global plan for rabies control by 2030:  support in establishing the global plan ZERO Rabies by 2030 a joined initiative by WHO, WOAH, FAO and GARC.
•  President of IABS (international Alliance for Biological Standardization) 2016-2022, member of the board of IABS, advisor to vaccine companies and various disease control initiatives.
• Member of the advisory board of the World Vaccine Congress.

  Present main activities and centers of interest: pandemic preparedness, platform technologies for vaccines and antibodies such as RNA, DNA, Scaffold subunits, viral vectors and fungi. Zoonoses and animal human spill overs.